Treatment after acquired resistance to EGFR-TKI of non-small cell lung cancer
10.3969/j.issn.1000-8179.2015.19.847
- VernacularTitle:表皮生长因子受体酪氨酸激酶抑制剂耐药后非小细胞肺癌治疗研究进展
- Author:
Gang CHENG
;
Bin AI
- Publication Type:Journal Article
- Keywords:
non-small cell lung cancer;
epidermal growth factor receptor mutation;
epidermal growth factor receptor tyrosine-ki-nase inhibitor;
resistance
- From:
Chinese Journal of Clinical Oncology
2015;42(19):942-946
- CountryChina
- Language:Chinese
-
Abstract:
Epidermal growth factor receptor tyrosine-kinase inhibitors (EGFR-TKIs) have elicited curative effects on patients with advanced non-small celllung cancer and with activating mutations in the EGFR gene. However, acquired resistance to EGFR-TKIs is eventually developed after an initial response is induced;as such, patients with acquired resistance must be treated with more ef-fective strategies to delay or possibly overcome the resistance. This article reviews available data on the treatment of patients who have failed to respond to EGFR-TKI.
